Cancer Biological Therapy Market Growth: Global Analysis, Industry Size, Share, Current Status, Segments and Trends by Forecast to 2024
Oct 22, 2019
This Global Cancer Biological Therapy market report studies the industry based on one or more segments covering key players, types, applications, products, technology, end-users, and regions for historical data as well as provides forecasts for next few years.
Delaware, Selbyville - October 22, 2019 /MarketersMedia/ —
Increasing R&D funding by government in various pharmaceutical, biopharmaceutical companies as well as research institutes involved in developing cancer drugs will foster cancer biologics market growth. Funds raised by governments in developed countries such as UK have facilitated cancer drug discovery process and has also enhanced operational capabilities of the companies and research centers involved in developing cancer biological therapy drugs and vaccines. Moreover, favorable government policies and regulatory framework facilitating drug discovery process will substantially augment cancer biologics industry growth. However, adverse effects of anti-cancer drug therapy may lower its preference and hamper business growth up to some extent.
Request a sample of this premium report at: https://www.marketstudyreport.com/request-a-sample/467761/?utm_source=Marketersmedia.com-AN
Cancer Biological Therapy Market will exceed USD 108 billion by 2024. Growing geriatric population will drive cancer biological therapy industry growth during forecast timeframe. Elderly population in the age group of 50 years and above is more susceptible to cancer that escalates demand for cancer biologic therapies. Cancer biological therapy is utilized to boost immune system and has commendable specificity that helps in faster recovery. High preference for cancer biological therapy for treating geriatric population suffering from cancer will positively influence industry growth over forthcoming years.
India cancer biological therapy market accounted for 18.3% revenue share in 2017 and is anticipated to have exponential growth during forecast timeframe. According to WHO, cancer is one of major causes of mortality and morbidity in India. Furthermore, availability of efficient cancer biological therapy has considerably increased survival rate in cancer patients. Aforementioned factors along with growing awareness regarding cancer treatment amongst people residing in rural India will trigger Indian cancer biological therapy industry growth during analysis period.
Vaccines segment was valued at USD 2.0 billion in 2017 and is expected to have considerable revenue size over forthcoming years. Vaccines utilized in cancer treatment possess high efficiency and have ability to increase immunity by recognizing and destroying specific antigens. Moreover, vaccines also create immunogenic response that reduces risk of acquiring cancer again in future and are most effective in treatment of bladder, breast and cervical cancer. Aforementioned factors coupled with growing incidences of breast cancer in developing economies such as India will stimulate segmental growth.
Germany cancer biological therapy market was valued at USD 4.0 billion in 2017. Increasing prevalence of cancer in Germany will surge demand for cancer biologics therapy. High prevalence of cancer will propel demand for cancer biologics thereby, enhancing Germany cancer biologics industry growth.
Request a discount on standard prices of this premium report at: https://www.marketstudyreport.com/check-for-discount/467761/?utm_source=Marketersmedia.com-AN
Some of the eminent industry players operating in cancer biological therapy industry includes AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Celgene Corporation, Eisai, ELI Lilly and Company, F. Hoffmann-La Roche, GlaxoSmithKline, Incyte, Merck, Novartis, Otsuka, Pfizer, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals and Takeda Pharmaceuticals. Key industry players implement several strategies such as mergers, acquisition, geographic expansions and new product launch that enables them to achieve sustainable profits.
Table of Content:
Chapter 1. Methodology
1.1. Methodology
1.2. Market definitions
1.3. Forecast parameters
1.4. Data sources
1.4.1. Secondary
1.4.1.1. Paid sources
1.4.1.2. Unpaid sources
1.4.2. Primary
Chapter 2. Executive Summary
2.1. Cancer biological therapy industry 360 degree synopsis, 2013 - 2024
2.1.1. Business trends
2.1.2. Product trends
2.1.3. Regional trends
Chapter 3. Cancer Biological Therapy Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2013 - 2024
3.3. Industry impact forces
3.3.1. Growth drivers
3.3.1.1. Increasing incidence of cancer worldwide
3.3.1.2. Growing geriatric population
3.3.1.3. Technological advancement in cancer biologics in developed countries
3.3.1.4. Increasing R&D funding coupled with favorable government policies
3.3.2. Industry pitfalls and challenges
3.3.2.1. High cost of treatment
3.3.2.2. Adverse effects of anti-cancer drug therapy
3.4. Growth potential analysis
3.4.1. By product
3.5. Porter's analysis
3.6. Competitive landscape, 2017
3.6.1. Strategy dashboard
3.7. PESTEL analysis
Chapter 4. Cancer Biological Therapy Market, By Product
4.1. Key segment trends
4.2. Monoclonal antibodies (MAB)
4.2.1. Market size, by region, 2013 - 2024
4.2.2. Naked MAB
4.2.2.1. Market size, by region, 2013 - 2024
4.2.3. Conjugated MAB
4.2.3.1. Market size, by region, 2013 - 2024
4.2.4. Bispecific MAB
4.2.4.1. Market size, by region, 2013 - 2024
4.3. Vaccines
4.3.1. Market size, by region, 2013 - 2024
4.3.2. Preventive vaccines
4.3.2.1. Market size, by region, 2013 - 2024
4.3.3. Therapeutic vaccines
4.3.3.1. Market size, by region, 2013 - 2024
4.4. Cancer growth blockers
4.4.1. Market size, by region, 2013 - 2024
4.4.2. Tyrosine kinase Inhibitors (TKI)
4.4.2.1. Market size, by region, 2013 - 2024
4.4.3. Proteasome Inhibitors (PI)
4.4.3.1. Market size, by region, 2013 - 2024
4.4.4. mTOR Inhibitors
4.4.4.1. Market size, by region, 2013 - 2024
4.5. Blood cell growth factors (BCGF)
4.5.1. Market size, by region, 2013 - 2024
4.5.2. Lenograstim
4.5.2.1. Market size, by region, 2013 - 2024
4.5.3. Filgrastim
4.5.3.1. Market size, by region, 2013 - 2024
4.6. Cytokines
4.6.1. Market size, by region, 2013 - 2024
4.6.2. Interferons
4.6.2.1. Market size, by region, 2013 - 2024
4.6.3. Interleukins
4.6.3.1. Market size, by region, 2013 - 2024
Chapter 5. Cancer Biological Therapy Market, By Region
Chapter 6 Company Profiles
For More Details on this Report: https://www.marketstudyreport.com/reports/cancer-biological-therapy-market
About Us:
Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.
Contact Info:
Name: Arun Hegde
Email: Send Email
Organization: Market Study Report LLC
Address: 4 North Main Street, Selbyville, Delaware 19975 USA
Phone: 1-302-273-0910
Website: https://www.marketstudyreport.com
Source: MarketersMedia
Release ID: 88929874